Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 2/20 | 0.41 |
| ▸ | TDP2 | O95551 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | BCL2 | P10415 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | S100A4 | P26447 | 3/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 3/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11358332 | 0.79 | ALDH1A1 (0.40) | MAPK1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1748980 | 0.76 | ALDH1A1 (0.41) | MAPTMAPK1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL28905016 | 0.74 | PTPRC (0.45) | MAPTMAPK1KDM4EALDH1A1APAF1 | |
| SCHEMBL284219 | 0.74 | — | — | |
| SCHEMBL25059985 | 0.73 | SLC2A1 (0.38) | MAPTMAPK1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL28490476 | 0.73 | CDC25B (0.39) | MAPTMAPK1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL29727870 | 0.73 | IDO1 (0.41) | MAPTMAPK1KDM4EAPAF1TDP2 | |
| SCHEMBL16047148 | 0.73 | IDO1 (0.41) | MAPTMAPK1KDM4EAPAF1TDP2 | |
| SCHEMBL276263 | 0.71 | HTR6 (0.40) | MAPTKDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL29137694 | 0.71 | NOTUM (0.41) | MAPTMAPK1KDM4EALDH1A1APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109734642-B | Synthesis and application of naphthalenone-sulfoxide ylide hybrid | 河南师范大学 | 2020-10-09 | — | — | CN | disclosed |
| US-10633369-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2020-04-28 | — | — | US | disclosed |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | 4 SC AG (DE) | 2018-07-19 | — | — | US | disclosed |
| US-9951050-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | 4SC DISCOVERY GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| US-8877929-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130123503-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-16 | — | — | US | disclosed |
| US-8357806-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120220774-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-30 | — | — | US | disclosed |
| US-8207341-B2 | Process or synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100056792-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056792-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | MAPT 3518/4885MAPK1 2733/4885KDM4E 1067/4885 |
| US-20130123503-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | MAPT 3518/4885MAPK1 2733/4885KDM4E 1067/4885 |
| US-10633369-B2 | Method of inhibiting DYRK1B | SMO, GLI1, GRK2 | MAPT 4239/4885MAPK1 1109/4885KDM4E 996/4885 |
| US-20120220774-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | MAPT 3518/4885MAPK1 2733/4885KDM4E 1067/4885 |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | MAPT 4239/4885MAPK1 1109/4885KDM4E 996/4885 |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | MAPT 4239/4885MAPK1 1109/4885KDM4E 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.